ttc-36 Antibody

Basic Research Questions

How to validate TTC36 antibody specificity across experimental models?

• Methodological guidance:

  • Use orthogonal validation techniques:

    • Immunoblotting: Confirm target band size (~21 kDa for full-length human TTC36) with positive/negative controls (e.g., TTC36-knockdown cell lysates) .

    • Immunohistochemistry (IHC): Compare staining patterns in tissues with known TTC36 expression (e.g., cytoplasmic localization in renal proximal tubules vs. reduced expression in liver cancer) .

    • Functional blocking: Pre-incubate antibodies with recombinant TTC36 protein to verify loss of signal .

  • Example validation data:

    Technique	Target Tissue	Observed Result	Citation
    WB	Human liver	Single band at 21 kDa
    IHC	Kidney	Cytoplasmic staining in proximal tubules

What experimental controls are critical for TTC36 studies in cancer research?

• Key controls:

  • Biological:

    • Paired tumor/adjacent normal tissue samples (e.g., liver cancer vs. para-carcinoma tissue) .

    • Cell lines with CRISPR-mediated TTC36 knockout or overexpression .

  • Technical:

    • Isotype-matched IgG for IHC/flow cytometry .

    • Western blot loading controls (e.g., GAPDH) with quantification of band intensity ratios .

How does TTC36 expression differ between normal and pathological states?

• Established findings:

  • Downregulation in cancers:

    • Liver cancer: 38D7 monoclonal antibody detects 60% reduction in TTC36 protein vs. adjacent tissue (immunohistochemistry score: tumor = 2.1 ± 0.3 vs. normal = 5.4 ± 0.7) .

    • Gastric cancer: TCGA data shows 4.2-fold lower TTC36 mRNA in tumors (P < 0.001) .

  • Upregulation in fibrosis:

    • Renal fibrosis: TTC36 expression increases 3.1-fold in obstructed kidneys (UUO model) vs. sham controls .

Advanced Research Questions

How to resolve contradictory findings on TTC36’s tumor-suppressive vs. pro-fibrotic roles?

• Analytical framework:

  • Context-dependent analysis:

    Context	Observed Role	Mechanism	Citation
    Liver cancer	Tumor suppressor	Induces apoptosis via caspase-3 activation
    Gastric cancer	Tumor suppressor	Inhibits Wnt/β-catenin (↓β-catenin by 55%)
    Renal fibrosis	Pathogenic	Enhances TGF-β/SMAD3 via CEBPB upregulation

  • Experimental strategies:

    • Tissue-specific knockout models (e.g., hepatocyte vs. renal tubular Cre lines).

    • Pathway inhibition studies (e.g., XAV939 for Wnt/β-catenin in gastric cancer ).

What molecular mechanisms link TTC36 to Wnt/β-catenin and TGF-β pathways?

• Mechanistic insights:

  • Wnt/β-catenin:

    • TTC36 overexpression reduces nuclear β-catenin by 40% in gastric cancer cells (AGS line) .

    • GSEA analysis shows enrichment of Wnt targets (FDR < 0.25) in TTC36-low gastric tumors .

  • TGF-β/SMAD3:

    • TTC36 binds C/EBPβ (CEBPB), increasing SMAD3 phosphorylation by 2.8-fold in HK2 cells .

  • Methodological recommendation:

    • Co-immunoprecipitation + mass spectrometry to identify novel TTC36 interactors.

Which in vivo models best recapitulate TTC36-related pathologies?

• Model comparison:

  Model	Phenotype	Utility	Citation
  UUO mice	TTC36 deficiency reduces fibrosis	Study renal EMT and TGF-β signaling
  Xenograft (GC)	TTC36 overexpression inhibits growth by 62%	Assess tumor suppression
  DEN-induced HCC	TTC36 knockdown accelerates tumorigenesis	Liver cancer progression

How to optimize TTC36 detection in low-abundance samples?

• Technical solutions:

  • Signal amplification:

    • Tyramide-based IHC (e.g., Opal™ Multiplex for co-staining with EMT markers).

  • Pre-analytical factors:

    • Antigen retrieval: HIER (pH 6.0) for formalin-fixed paraffin-embedded tissues .

    • Antibody concentration: Titrate between 0.5–2 µg/mL for WB .